CD274 and neoplasm: Cohort 1 included patients with Response Evaluation Criteria in Solid Tumors (RECIST)-measurable, PD-L1 positive disease, using a combined positive score (CPS) of ≥1 to define positivity (n = 133), where CPS is the number of PD-L1 positive cells, including immune cells and tumor cells, divided by the total number of tumor cells, multiplied by 100 [51,52].